ABBV – AbbVie Inc.
ABBV — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.42
Margin Of Safety %
16
Put/Call OI Ratio
1.06
EPS Next Q Diff
-2.37
EPS Last/This Y
12.17
EPS This/Next Y
1.58
Price
209.33
Target Price
255.27
Analyst Recom
1.76
Performance Q
-8.91
Upside
-75.2%
Beta
0.38
Ticker: ABBV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | ABBV | 234.23 | 0.93 | 0.75 | 222046 |
| 2026-03-04 | ABBV | 236.24 | 0.93 | 0.38 | 228423 |
| 2026-03-05 | ABBV | 232.25 | 0.90 | 0.63 | 233536 |
| 2026-03-09 | ABBV | 227.47 | 0.94 | 0.68 | 231401 |
| 2026-03-10 | ABBV | 226.98 | 0.95 | 0.64 | 234229 |
| 2026-03-11 | ABBV | 227.68 | 0.94 | 1.08 | 237274 |
| 2026-03-12 | ABBV | 225.28 | 0.94 | 0.84 | 238582 |
| 2026-03-17 | ABBV | 219.78 | 0.96 | 0.90 | 238608 |
| 2026-03-18 | ABBV | 208.33 | 0.96 | 0.78 | 243009 |
| 2026-03-19 | ABBV | 206.21 | 0.98 | 0.69 | 252965 |
| 2026-03-20 | ABBV | 205.07 | 1.00 | 1.53 | 253853 |
| 2026-03-23 | ABBV | 204.94 | 1.12 | 0.38 | 207373 |
| 2026-03-24 | ABBV | 205.2 | 1.08 | 0.51 | 213697 |
| 2026-03-25 | ABBV | 207.17 | 1.07 | 0.80 | 215998 |
| 2026-03-26 | ABBV | 210.52 | 1.06 | 0.67 | 218609 |
| 2026-03-27 | ABBV | 209.33 | 1.06 | 0.55 | 222813 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | ABBV | 232.10 | 22.3 | 22422.9 | 14.53 |
| 2026-03-02 | ABBV | 234.21 | 22.3 | 22287.3 | 14.53 |
| 2026-03-03 | ABBV | 233.85 | 22.5 | 21988.3 | 14.53 |
| 2026-03-04 | ABBV | 236.24 | 22.5 | 22315.1 | 14.53 |
| 2026-03-05 | ABBV | 232.33 | 22.5 | 21587.7 | 14.53 |
| 2026-03-06 | ABBV | 230.06 | 22.5 | 21768.0 | 14.53 |
| 2026-03-09 | ABBV | 227.49 | 22.5 | 21771.0 | 14.53 |
| 2026-03-10 | ABBV | 226.96 | 22.6 | 21977.4 | 14.53 |
| 2026-03-11 | ABBV | 227.68 | 22.6 | 22116.8 | 14.53 |
| 2026-03-12 | ABBV | 225.33 | 22.6 | 21754.3 | 14.53 |
| 2026-03-13 | ABBV | 219.70 | 22.6 | 21349.6 | 14.53 |
| 2026-03-17 | ABBV | 219.82 | 22.6 | 21835.9 | 14.53 |
| 2026-03-18 | ABBV | 208.30 | 22.6 | 20619.1 | 14.53 |
| 2026-03-19 | ABBV | 206.22 | 22.6 | 19323.0 | 14.53 |
| 2026-03-20 | ABBV | 205.02 | 22.6 | 19430.2 | 14.53 |
| 2026-03-23 | ABBV | 204.95 | 22.6 | 19560.9 | 14.54 |
| 2026-03-24 | ABBV | 205.18 | 22.6 | 19606.2 | 14.54 |
| 2026-03-25 | ABBV | 207.15 | 22.6 | 19811.8 | 14.54 |
| 2026-03-26 | ABBV | 211.09 | 22.6 | 20045.2 | 14.54 |
| 2026-03-27 | ABBV | 209.33 | 22.6 | 19365.8 | 14.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | ABBV | -1.04 | 0.85 | 1.30 |
| 2026-03-02 | ABBV | -1.04 | 1.28 | 1.30 |
| 2026-03-03 | ABBV | -0.96 | 1.28 | 1.30 |
| 2026-03-04 | ABBV | -1.75 | 1.28 | 1.30 |
| 2026-03-05 | ABBV | -1.75 | 1.28 | 1.30 |
| 2026-03-06 | ABBV | -1.75 | 1.28 | 1.30 |
| 2026-03-09 | ABBV | -1.97 | 1.33 | 1.30 |
| 2026-03-10 | ABBV | -1.97 | 1.33 | 1.30 |
| 2026-03-11 | ABBV | -1.97 | 1.33 | 1.23 |
| 2026-03-12 | ABBV | -1.97 | 1.33 | 1.23 |
| 2026-03-13 | ABBV | -1.97 | 1.33 | 1.23 |
| 2026-03-17 | ABBV | -1.97 | 1.37 | 1.23 |
| 2026-03-18 | ABBV | -1.97 | 1.37 | 1.23 |
| 2026-03-19 | ABBV | -1.97 | 1.37 | 1.23 |
| 2026-03-20 | ABBV | -1.97 | 1.37 | 1.23 |
| 2026-03-23 | ABBV | -1.97 | 1.37 | 1.23 |
| 2026-03-24 | ABBV | -1.97 | 1.37 | 1.23 |
| 2026-03-25 | ABBV | -1.97 | 1.37 | 1.42 |
| 2026-03-26 | ABBV | -1.97 | 1.37 | 1.42 |
| 2026-03-27 | ABBV | -1.97 | 1.37 | 1.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.15
Avg. EPS Est. Current Quarter
3.01
Avg. EPS Est. Next Quarter
3.78
Insider Transactions
-1.97
Institutional Transactions
1.37
Beta
0.38
Average Sales Estimate Current Quarter
14716
Average Sales Estimate Next Quarter
16824
Fair Value
242.19
Quality Score
68
Growth Score
86
Sentiment Score
72
Actual DrawDown %
14.5
Max Drawdown 5-Year %
-21.9
Target Price
255.27
P/E
88.68
Forward P/E
12.93
PEG
0.61
P/S
6.05
P/B
P/Free Cash Flow
20.78
EPS
2.36
Average EPS Est. Cur. Y
14.54
EPS Next Y. (Est.)
16.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
6.84
Relative Volume
0.79
Return on Equity vs Sector %
-155.4
Return on Equity vs Industry %
-164.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
19365.8
◆
ABBV
Healthcare
$209.40
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37.6
Range 1M
25.8%
Sup Dist
0.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
45.7%
EPS NY
11.1%
52W%
57.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+43.8% upside
Upside
+43.8%
Quality
68
MoS
16%
AbbVie Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 57000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV
Latest News
—
Caricamento notizie per ABBV…
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading